福岡新水巻病院における急性細菌性前立腺炎に対する抗菌薬治療の現状 －特にニューキノロン系抗菌薬の有用性の評価－

Treatment outcome of antibiotic therapy for acute bacterial prostatitis －Efficacy of new quinolone antibacterial drugs－

　福岡新水巻病院で2007年１月～2011年11月までの５年間に，発熱をともなう急性細菌性前立腺炎として入院加療した49例（53エピソード）を対象に抗菌薬治療の現状を検討した。初期治療薬としてパズフロキサシン（pazufloxacin：PZFX）が42例に，その他の抗菌薬が11例に使用された。PZFXが有効であった症例は35例（83.3％）で，すべて経口抗菌薬へ移行でき，治療完遂した。その他の抗菌薬が使用された11例はすべて，それらの薬剤に感受性があり，臨床効果も有効で，全症例において経口抗菌薬へ移行でき，治療完遂した。急性細菌性前立腺炎に対する初期治療薬としてPZFXは依然として有効であるが，キノロン耐性菌が増加しており，薬剤感受性にあわせた抗菌薬の変更をすみやかに行う必要がある。

　We examined the treatment outcome of antibacterial drugs in 49 patients（53 episodes）who were hospitalized due to acute bacterial prostatitis with fever during a 5-year period（from January 2007 to November 2011）. For 42 episodes, pazufloxacin（PZFX）was used as the first-line therapy, whereas, for the remaining 11 episodes antibiotic drugs other than PZFX were used. PZFX therapy was effective in 35 episodes（83.3％）and in those patients who were effectively treated with PZFX, treatments were subsequently switched to oral antimicrobial agents and completed by the full course administration. Antibiotic drugs other than PZFX also showed high sensitivity in all 11 episodes, and the clinical response was effective. All patients who were initially treated with parenteral antimicrobials other than PZFX were also later switched to being on oral antimicrobial agents until the completion of full course administration. PZFX is an effective initial therapy option for acute bacterial prostatitis. However, switching or changing to other more appropriate antimicrobials based on the drug sensitivity is needed because of increasing emergence of quinolone resistant bacteria.